Chun-Chin Chang1, Chien-Yi Hsu2, Po-Hsun Huang3, Chia-Hung Chiang4, Shao-Sung Huang5, Hsin-Bang Leu5, Chin-Chou Huang6, Jaw-Wen Chen7, Shing-Jong Lin8. 1. Division of Cardiology, Department of Medicine; ; Cardiovascular Research Center; 2. Cardiovascular Research Center; ; Institute of Clinical Medicine, National Yang-Ming University, Taipei; ; Department of Medicine, Taipei Veterans General Hospital Yuli Branch, Hualien, Taiwan. 3. Division of Cardiology, Department of Medicine; ; Cardiovascular Research Center; ; Institute of Clinical Medicine, National Yang-Ming University, Taipei; 4. Cardiovascular Research Center; ; Institute of Clinical Medicine, National Yang-Ming University, Taipei; 5. Division of Cardiology, Department of Medicine; ; Healthcare and Management Center, Taipei Veterans General Hospital; ; Cardiovascular Research Center; ; Institute of Clinical Medicine, National Yang-Ming University, Taipei; 6. Division of Cardiology, Department of Medicine; ; Department of Medical Education; ; Cardiovascular Research Center; ; Institute of Pharmacology; 7. Division of Cardiology, Department of Medicine; ; Division of Clinical Research; ; Cardiovascular Research Center; ; Institute of Pharmacology; 8. Division of Cardiology, Department of Medicine; ; Department of Medical Research; ; Cardiovascular Research Center; ; Institute of Clinical Medicine, National Yang-Ming University, Taipei;
Abstract
BACKGROUND: Bilirubin has emerged as an important endogenous antioxidant molecule, and increasing evidence shows that bilirubin may protect against atherosclerosis. The SYNTAX score has been developed to assess the severity and complexity of coronary artery disease. The aim of this study was to evaluate whether serum bilirubin levels are associated with SYNTAX scores and whether they could be used to predict future cardiovascular events in patients undergoing coronary intervention. METHODS: Serum bilirubin levels and other blood parameters in patients with at least 12-h fasting states were determined. The primary endpoint was any composite cardiovascular event within 1 year, including death, nonfatal myocardial infarction, and target-vessel revascularization. RESULTS: In total, 250 consecutive patients with stable coronary artery disease (mean age 70 ± 13) who had received coronary intervention were enrolled. All study subjects were divided into two groups: group 1 was defined as high SYNTAX score (> 22), and group 2 was defined as low SYNTAX score (≤ 22). Total bilirubin levels were significantly lower in the high SYNTAX score group than in the low SYNTAX score group (0.51 ± 0.22 vs. 0.72 ± 0.29 mg/dl, p < 0.001). By multivariate analysis, serum total bilirubin levels were identified as an independent predictor for high SYNTAX score (adjusted odds ratio: 0.28, 95% confidence interval 0.04-0.42; p = 0.004). Use of the Kaplan-Meier analysis demonstrated a significant difference in 1-year cardiovascular events between high (> 0.8 mg/dl), medium (> 0.5, ≤ 0.8 mg/dl), and low (≤ 0.5 mg/dl) bilirubin levels (log-rank test p = 0.011). CONCLUSIONS: Serum bilirubin level is associated with SYNTAX score and predicts future cardiovascular events in patients undergoing coronary intervention.
BACKGROUND:Bilirubin has emerged as an important endogenous antioxidant molecule, and increasing evidence shows that bilirubin may protect against atherosclerosis. The SYNTAX score has been developed to assess the severity and complexity of coronary artery disease. The aim of this study was to evaluate whether serum bilirubin levels are associated with SYNTAX scores and whether they could be used to predict future cardiovascular events in patients undergoing coronary intervention. METHODS: Serum bilirubin levels and other blood parameters in patients with at least 12-h fasting states were determined. The primary endpoint was any composite cardiovascular event within 1 year, including death, nonfatal myocardial infarction, and target-vessel revascularization. RESULTS: In total, 250 consecutive patients with stable coronary artery disease (mean age 70 ± 13) who had received coronary intervention were enrolled. All study subjects were divided into two groups: group 1 was defined as high SYNTAX score (> 22), and group 2 was defined as low SYNTAX score (≤ 22). Total bilirubin levels were significantly lower in the high SYNTAX score group than in the low SYNTAX score group (0.51 ± 0.22 vs. 0.72 ± 0.29 mg/dl, p < 0.001). By multivariate analysis, serum total bilirubin levels were identified as an independent predictor for high SYNTAX score (adjusted odds ratio: 0.28, 95% confidence interval 0.04-0.42; p = 0.004). Use of the Kaplan-Meier analysis demonstrated a significant difference in 1-year cardiovascular events between high (> 0.8 mg/dl), medium (> 0.5, ≤ 0.8 mg/dl), and low (≤ 0.5 mg/dl) bilirubin levels (log-rank test p = 0.011). CONCLUSIONS: Serum bilirubin level is associated with SYNTAX score and predicts future cardiovascular events in patients undergoing coronary intervention.
Authors: João Brito; Rui Teles; Manuel Almeida; Pedro de Araújo Gonçalves; Luis Raposo; Pedro Sousa; Miguel Mendes Journal: J Invasive Cardiol Date: 2011-12 Impact factor: 2.022
Authors: Libor Vítek; Milan Jirsa; Marie Brodanová; Milan Kalab; Zdenek Marecek; Vilém Danzig; Ladislav Novotný; Petr Kotal Journal: Atherosclerosis Date: 2002-02 Impact factor: 5.162
Authors: Robert Ollinger; Martin Bilban; Anna Erat; Alberto Froio; James McDaid; Shivraj Tyagi; Eva Csizmadia; Aurelio V Graça-Souza; Angela Liloia; Miguel P Soares; Leo E Otterbein; Anny Usheva; Kenichiro Yamashita; Fritz H Bach Journal: Circulation Date: 2005-08-08 Impact factor: 29.690
Authors: Omer Sahin; Mahmut Akpek; Deniz Elcik; Serhat Karadavut; Vedat Simsek; Murat Tulmac; Ozcan Orscelik; Bekir Calapkorur; Ali Ergin; Mehmet G Kaya Journal: Angiology Date: 2012-04-09 Impact factor: 3.619
Authors: Patrick W Serruys; Marie-Claude Morice; A Pieter Kappetein; Antonio Colombo; David R Holmes; Michael J Mack; Elisabeth Ståhle; Ted E Feldman; Marcel van den Brand; Eric J Bass; Nic Van Dyck; Katrin Leadley; Keith D Dawkins; Friedrich W Mohr Journal: N Engl J Med Date: 2009-02-18 Impact factor: 91.245